Thais Cristina Prado de Souza

Mrs. Thais Cristina Prado de Souza

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 December 2024 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
RMRaiane Aparecida dos Santos Machado
Raiane Aparecida dos Santos Machado
RSRaoni Pais Siqueira
Raoni Pais Siqueira
FSFernanda Cardoso da Silva
Fernanda Cardoso da Silva
AMAndré Carlos Pereira Matos
André Carlos Pereira Matos
DBDayanne Silva Borges
Dayanne Silva Borges
TAThaise Gonçalves Araújo
Thaise Gonçalves Araújo
Background/Objectives: Triple-negative breast cancer (TNBC) is the most challenging molecular subtype of breast cancer (BC) in clinical practice, associated with a worse prognosis due to limited treatment strategies and its insensitivity to conventional drugs. Zinc is an important trace element for homeostasis, and its Schiff base metal complexes have shown promise in treating advanced tumors. In this study, four new heteroleptic Zn(II) complexes (1–4) with Schiff bases were synthesized, characterized, and evaluated for their activity in BC cells. Methods: Compounds were synthesized, characterized, and their crystal structures were determined. Biological activity was assessed using MTT, clonogenic, scratch wound healing, caspase 3 and 8 activity, qPCR, and chemosensitization assays. Results: The complexes exhibited cytotoxicity against MCF-7 (luminal BC), MDA-MB-453 (HER2-positive BC), and MDA-MB-231 (TNBC) cell lines, with IC50 values ranging from 0.01 to 20 µM. Complex 4 showed reduced cytotoxicity toward non-tumor cell lines. This, complexation with Zn(II) increased the cytotoxicity of the ligands, a trend not observed for complexes 1–3. Due to its favorable profile, complex 4 was selected for further assays, in which it inhibited colony formation and the cell migration of TNBC cells in a dose-dependent manner. Furthermore, this compound induced cell death independently of caspases, decreasing the activity of caspase 8. Interestingly, complex 4 sensitized TBNC cells to doxorubicin and paclitaxel, possibly modulating the epithelial–mesenchymal transition mechanism, as evidenced by increased CDH1 expression. Conclusions: Results suggest the potential of complex 4 in sensitizing aggressive BC cells to chemotherapy, proving to be a promising alternative in cases of therapeutic failure.

8 July 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
TSThais Cristina Prado de Souza
Thais Cristina Prado de Souza
LSLucas Bonelli Silva
Lucas Bonelli Silva
RSRafael Aparecido Carvalho Souza
Rafael Aparecido Carvalho Souza
ANAdelino Vieira de Godoy Netto
Adelino Vieira de Godoy Netto
FRFillipe V. Rocha
Fillipe V. Rocha
Carolina OliveiraCarolina Oliveira
Carolina Oliveira
The present work reports the synthesis, characterization and biological application as antiproliferative agents of two new thiosemicarbazides and four binuclear platinum(II) and palladium(II) complexes. The ligands H2LCh and H2LPh were used for the synthesis of four novel complexes [{Pd(LCh)Cl(PPh3)}2] (1), [{Pd(LPh)Cl(PPh3)}2] (2), [{Pt(LCh)Cl(PPh3)}2] (3), and [{Pt(LPh)Cl(PPh3)}2] (4). The compounds were characterized by spectroscopic methods such as FTIR, 1H and 31P NMR. Single–crystal X–ray diffraction confirmed the proposed structure for complexes 1, 2 and 3. In all cases, the Schiff base ligands coordinate in a bidentate mode via imine nitrogen and sulfur atoms, with two metal centers, forming dinuclear complexes. Additional donor atoms as a phosphorus from PPh3 ligand and a chlorine ion complete the coordination sphere with a square-planar geometry. The theoretical prediction of the interaction of the human topoisomerase enzyme with the dinuclear complexes of Pd(II) and Pt(II) shows that the complexes with the phenyl groups couple better and more favorably mainly through bond interactions and hydrophobic interactions. The antiproliferative properties in vitro of the free ligands and metal complexes have been investigated against A2780 (ovarian tumor), A2780cis (cisplatin–resistant ovarian tumor), A549 (lung tumor), SK–BR-3 (breast tumor) and MRC–5 (non–lung tumor of fetal origin). The results show an increase in activity after the complexation of the thiosemicarbazide to metal centre of palladium(II) against ovarian cancer cells.

7 August 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
TSThais Cristina Prado de Souza
Thais Cristina Prado de Souza
RSRafael Aparecido Carvalho Souza
Rafael Aparecido Carvalho Souza
LDLuana da Silva Dorneles
Luana da Silva Dorneles
CCClaudio T. Carvalho
Claudio T. Carvalho
GPGabriele de Menezes Pereira
Gabriele de Menezes Pereira
Carolina OliveiraCarolina Oliveira
Carolina Oliveira
Two new indole-based thiosemicarbazone ligands, HT1 and HT2, were synthesized by condensation of 3-methyl-1H-indol-2-carboxaldehyde with 4-methyl and 4-phenyl-3-thiosemicarbazide, respectively. These ligands were used to prepare four palladium(II) complexes containing triphenylphosphine (PPh3) or 1,3,5-triaza-7-phosphaadamantane (PTA), namely PdT1PPh3 (1), PdT1PTA (2), PdT2PPh3 (3) and PdT2PTA (4). The compounds were characterized by spectroscopic methods, HRMS, and single-crystal X-ray diffraction for HT1. Spectroscopic techniques (FTIR and NMR) indicated coordination of the ligands to palladium ion via nitrogen and sulfur atoms. HRMS analyses provided further confirmation of the proposed molecular formulations and the structural integrity of the ligands and complexes. Single-crystal X–ray diffraction confirmed the molecular structure of HT1 and revealed its solid-state organization driven by hydrogen-bonding interactions. The synthesized complexes containing PTA exhibited significantly greater cytotoxicity than their analogs containing PPh3. PdT1PTA and PdT2PTA complexes showed IC50 values in the submicromolar range for both A2780 cells (IC50 = 0.108 ± 0.023 µM and 0.146 ± 0.008 µM) and the cisplatin-resistant A2780cis cell line (IC50 = 0.427 ± 0.044 µM and 0.122 ± 0.033 µM), while maintaining lower toxicity to non-tumor MRC-5 fibroblasts (IC50 = 1.8 ± 0.4 µM and 2.87 ± 0.48 µM). PdT2PTA was the most active and selective derivative, while PdT2PPh3 showed no antiproliferative effects. LIVE/DEAD fluorescence imaging assays performed with PdT2PTA in A2780cis cells revealed a dose-dependent reduction in viable cell count. Exploratory molecular docking studies suggested favorable DNA-binding interactions for PdT2PTA, followed by PdT1PTA, in agreement with the antiproliferative results.